BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Acquired by Assetmark Inc.

Assetmark Inc. lifted its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 19.2% in the first quarter, Holdings Channel reports. The firm owned 29,569 shares of the company’s stock after buying an additional 4,755 shares during the period. Assetmark Inc.’s holdings in BeOne Medicines were worth $8,781,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Mariner LLC lifted its stake in BeOne Medicines by 3.8% in the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after buying an additional 32 shares in the last quarter. Signaturefd LLC grew its holdings in shares of BeOne Medicines by 10.7% during the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after buying an additional 33 shares in the last quarter. Farther Finance Advisors LLC boosted its position in BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after acquiring an additional 39 shares during the last quarter. CWM LLC boosted its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Benjamin Edwards Inc. grew its stake in BeOne Medicines by 8.0% during the 4th quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after acquiring an additional 51 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Trading Down 0.5%

Shares of ONC stock opened at $310.58 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $253.95 and a 1-year high of $385.22. The firm has a market cap of $34.08 billion, a PE ratio of 69.48 and a beta of 0.49. The company has a 50-day moving average of $290.21 and a two-hundred day moving average of $308.99. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion for the quarter. On average, analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ONC. Wolfe Research began coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price on the stock. Barclays reduced their price objective on BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 14th. Citizens Jmp restated a “market outperform” rating and issued a $396.00 target price on shares of BeOne Medicines in a report on Wednesday, July 1st. Wells Fargo & Company started coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $390.92.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, insider Lai Wang sold 1,068 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $276.74, for a total transaction of $295,558.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Chan Henry Lee sold 664 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $302.46, for a total value of $200,833.44. Following the transaction, the senior vice president owned 202 shares of the company’s stock, valued at approximately $61,096.92. This represents a 76.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 233,647 shares of company stock worth $70,335,553 in the last ninety days. 6.19% of the stock is owned by company insiders.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.